Pedro Paez Gonzalez, MD
Cardiovascular Disease · San Juan, PRNPI 1992714133
Payments from drug & device makers
Across 56 payments — averaging $55.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$2K
- Boehringer Ingelheim$525
- PBG Puerto Rico LLC$320
- Sanofi-aventis U.S. LLC$200
- Johnson & Johnson$170
- AstraZeneca$89
- plus $255 from 7 others
What the payments were for
- Speaking & faculty fees$1,70054%
- Food & beverage$1,36044%
- Gifts$592%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 2 | $1,560 |
| Boehringer Ingelheim | 17 | $525 |
| PBG Puerto Rico LLC | 16 | $320 |
| Sanofi-aventis U.S. LLC | 1 | $200 |
| Johnson & Johnson | 7 | $170 |
| AstraZeneca | 5 | $89 |
| Smith+Nephew | 1 | $71 |
| Mannkind Corporation | 1 | $59 |
| Bayer | 2 | $35 |
| Novo Nordisk | 1 | $25 |
| Sanofi Pasteur Inc. | 1 | $24 |
| AbbVie | 1 | $23 |
| Genentech USA, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- STEGLATRO$1,500
- SOTAGLIFLOZIN$200
How this compares
$3,120 in reported general payments places this provider in the 50th percentile of 267 cardiovascular disease providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 166 | $160,297 |
| SynthroidLevothyroxine Sodium | 1,086 | $138,980 |
| EliquisApixaban | 107 | $138,307 |
| JardianceEmpagliflozin | 104 | $132,794 |
| JanumetSitagliptin Phos/Metformin Hcl | 116 | $118,106 |
| XareltoRivaroxaban | 77 | $90,950 |
| JanuviaSitagliptin Phosphate | 60 | $80,786 |
| TradjentaLinagliptin | 28 | $39,236 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 38 | $34,224 |
| PrezcobixDarunavir/Cobicistat | 12 | $29,926 |
| JentaduetoLinagliptin/Metformin Hcl | 19 | $28,533 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 31 | $26,927 |
| TivicayDolutegravir Sodium | 11 | $25,410 |
| DescovyEmtricitabine/Tenofov Alafenam | 11 | $24,528 |
| CreonLipase/Protease/Amylase | 13 | $23,654 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Trijardy Xr, Jentadueto, Synjardy Xr | $525 | $245,123205 claims |
| MerckJanumet, Januvia, Janumet Xr | $1,560 | $225,818207 claims |
| AstraZenecaFarxiga, Symbicort | $89 | $167,205190 claims |
| AbbVieSynthroid, Creon | $23 | $162,6341,099 claims |
| Johnson & JohnsonXarelto, Prezcobix | $170 | $120,87689 claims |
| Sanofi-aventis U.S. LLCLantus | $200 | $13,16362 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 267 cardiovascular disease providers in Puerto Rico.
Other cardiovascular disease in San Juan
- Manuel GuzmanSan Juan$203K
- Sonia VicentySan Juan$69K
- Ramon PereaSan Juan$68K
- Sonia Velazquez-NavarroSan Juan$65K
- Francisco Merced-OrtizSan Juan$54K
- Edwin Rodriguez CruzSan Juan$22K
- Pedro Vargas-OteroSan Juan$15K
- Ricardo ColacioppoSan Juan$14K
- Jose Kareh CorderoSan Juan$13K
- William Borges CancelSan Juan$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.